Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer

Papillary thyroid cancer (PTC) accounts for about 90% of thyroid cancer. There are approximately 20%–30% of PTC patients showing disease persistence/recurrence and resistance to radioactive iodine (RAI) treatment. For these PTC patients with RAI refractoriness, the prognosis is poor. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lina, Shi, Yuhong, Lai, Qian, Huang, Yuan, Jiang, Xue, Liu, Qian, Huang, Ying, Xia, Yuxiao, Xu, Dongkun, Jiang, Zhiqiang, Tu, Wenling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132198/
https://www.ncbi.nlm.nih.gov/pubmed/35634509
http://dx.doi.org/10.3389/fendo.2022.865909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132198/
https://www.ncbi.nlm.nih.gov/pubmed/35634509
http://dx.doi.org/10.3389/fendo.2022.865909

Ejemplares similares